MorphoSys, a leader in antibody drug discovery, has emerged as a top 50 big biotech company with its product pipeline and partnering strategy. The big biotech company, based in Germany, is a successful antibody library developer. The company is constantly looking for innovative technology platforms and opportunities to collaborate with innovative science driven organizations and academic institutes.
The company’s partnering activity is reviewed in this article. The following figure shows the level of MorphoSys partnering deal announcements since 2009.
Figure 1: MorphoSys partnering deals 2009-2014
Figure 1: MorphoSys partnering deals 2009-2014
Source: Current Agreements, 2014
The figure above observes the high partnering activity carried out by MorphoSys. On average 4 deals have been signed since 2009 each year. The company’s core business strategy is to broaden its product portfolio by partnering which makes it a sought after partner by big pharma and biotech companies.
The company boasts of developing HuCAL technology which is a novel antibody library technology which has gained huge success in the pharma industry.
The following table provides an overview of the partnering deals announced by MorphoSys based on therapy area disclosed. Our report provides a more detailed insight into the precise therapeutic target of each deal.
See: Report: Partnering Agreements with MorphoSys 2009-2014
Figure 2: MorphoSys partnering deals by therapy area 2009-2014
Figure 2: MorphoSys partnering deals by therapy area 2009-2014
Source: Current Agreements, 2014
Further analysis of these deals shows that MorphoSys has a preference for licensing and collaborative R&D deals, similar to many other top pharmaceutical or big biotech companies. Such partnering deals provide the right for MorphoSys to exploit the licensors technology in return for payment of upfront, development and sales, and royalty payments.
The following table provides an overview of the partnering deals announced by MorphoSys based on deal type disclosed.
Figure 3: MorphoSys partnering deals by deal type 2009-2014
Figure 3: MorphoSys partnering deals by deal type 2009-2014
Source: Current Agreements, 2014
Morphosys, a leader in antibody drug discovery, partners and looks for partners at late preclinical stage and early clinical stages for in-licensing and co- development deals.
The following table provides an overview of the partnering deals announced by MorphoSys based on stage of development at signature.
Figure 4: MorphoSys partnering by stage of development 2009-2014
Figure 4: MorphoSys partnering by stage of development 2009-2014
Source: Current Agreements, 2014
MorphoSys has signed over 25 partnering, collaborative R&D and licensing deals since 2009. Partnering with companies like MorphoSys, Merck Serono and Janssen Biotech in discovery and pre-clinical stages, the company has bolstered its position in the cancer and rheumatoid arthritis disease areas.
Morphosys’ recent high value deals with big pharma companies Celgene and GSK to co-develop antibodies MOR202 and MOR103 respectively are shown below in the table.
Figure 5: Top MorphoSys partnering deals by headline value 2009-2014
Figure 5: Top MorphoSys partnering deals by headline value 2009-2014
Source: Current Agreements, 2014
Morphosys has proven to be actively involved in partnering activity for a very long term with industries globally. The company is constantly on the lookout for innovative companies with technology platform and products to seek co-development and in-licensing opportunities.
Our report provides more detailed insight into the details of each deal.
See: Report: Partnering Agreements with MorphoSys 2009-2014
MorphoSys partnering at Current Agreements
View all partnering deals for MorphoSys: 2014 | 2013 | 2012 | 2011 | 2010 | 2009
Full details on each deal can be found at CurrentAgreements (subscription required)
Or purchase report: Report: Partnering Agreements with MorphoSys 2009-2014
More
Summary profile data for MorphoSys
Partnering interests for MorphoSys
No M&A activity for MorphoSys
Available reports from Current Partnering
Report: Partnering Agreements with MorphoSys 2009-2014
Report: Partnering Deals and Alliances with Big Biotech
Available resources for deal coverage for MorphoSys
Subscribe: Current Agreements life sciences partnering, M&A and financing deals database – find out more
Read: more on MorphoSys company profile, recent partnering, M&A and financing news and articles
Related
Report: Finding Biopharma Licensing and Collaboration Partners
Report: Partnering Deals and Aliances with Big Pharma
View: CP Insight’s Partnering Scorecard – view top life science partnering deals by value
View: CP Insight’s M&A Scorecard – view top life science M&A deals by value
View: CP Insight Deal Monitor’s Deal Metrics – the latest deal trend infographics for life science deal making
View: CP Insight’s Big Pharma Deal Making Activity – latest trends in big pharma deal making activity
View: CP Insight’s Big Biotech Deal Making Activity- latest trends in big biotech deal making activity
Signup: Current Partnering Dealmakers Update – weekly newsletter providing the latest life science industry deal news, deal making trends, partnering events – sign up now
Signup: Current Agreements Deals Review – monthly newsletter – reviewing the previous month’s life science deal making – partnering, M&A and financing – sign up now
View: CP Insight’s Top 50 pharma – overview of top 50 pharmaceutical companies by revenue – partnering activity, deal news, partnering dealtalk
View: CP Insights’s Top 50 biotech – overview of top 50 biotechnology companies by revenue – partnering activity, deal news, partnering dealtalk
Follow us on: LinkedIn Current Partnering | LinkedIn Business Development Network | @Currentpartner on Twitter
The post MorphoSys: Partnering activity 2009-2014 appeared first on .